

# PF 43(4) Table of Contents

## Publish date: July 3, 2017

---

### **PROPOSED IRA**

[Proposed Interim Revision Announcements](#)

### **IN-PROCESS REVISION**

[In-Process Revision](#)

### **GENERAL CHAPTERS**

[<5> Inhalation and Nasal Drug Products - General Information and Product Quality Tests \(USP41-NF36 2S\)](#)

[<121> Insulin Assays \(USP41-NF36 2S\)](#)

[<856> Near-Infrared Spectroscopy \[NEW\] \(USP41-NF36 2S\)](#)

[<858> Raman Spectroscopy \[NEW\] \(USP41-NF36 2S\)](#)

[<861> Sutures - Diameter \(USP41-NF36 2S\)](#)

[<871> Sutures - Needle Attachment \(USP41-NF36 2S\)](#)

[<881> Tensile Strength \(USP41-NF36 2S\)](#)

[<1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products \(USP41-NF36 2S\)](#)

[<1099> Limit On Number of Large Deviations When Assessing Content Uniformity In Large Samples \[NEW\] \(USP41-NF36 2S\)](#)

[<1119> Near-Infrared Spectroscopy \(USP41-NF36 2S\)](#)

[<1120> Raman Spectroscopy \(USP41-NF36 2S\)](#)

### **REAGENTS, INDICATORS, AND SOLUTIONS**

#### **Reagent Specifications**

[Ethyl p-Toluenesulfonate \[NEW\] \(USP41-NF36 2S\)](#)

[Packings for High-Pressure Liquid Chromatography \(USP41-NF36 2S\)](#)

[Phases for Gas Chromatography \(USP41-NF36 2S\)](#)

[Supports for Gas Chromatography \(USP41-NF36 2S\)](#)

#### **Chromatographic Columns**

[L111 \[NEW\] \(USP41-NF36 2S\)](#)

[L113 \[NEW\] \(USP41-NF36 2S\)](#)

### **REFERENCE TABLES**

#### **Container Specifications**

[Container Specifications \[NEW\] \(USP41-NF36 2S\)](#)

#### **Description and Solubility**

[Description and Relative Solubility of USP and NF Articles \(USP41-NF36 2S\)](#)

[Description and Solubility - C](#)

[Description and Solubility - D](#)

[Description and Solubility - I](#)

[Description and Solubility - T](#)

## **USP MONOGRAPHS**

[Acetazolamide \(USP41-NF36 2S\)](#)

[Amantadine Hydrochloride \(USP41-NF36 2S\)](#)

[Amantadine Hydrochloride Capsules \(USP41-NF36 2S\)](#)

[Amantadine Hydrochloride Oral Solution \(USP41-NF36 2S\)](#)

[Azithromycin for Oral Suspension \(USP41-NF36 2S\)](#)

[Bicalutamide Tablets \(USP41-NF36 2S\)](#)

[Captopril Tablets \(USP41-NF36 2S\)](#)

[Captopril and Hydrochlorothiazide Tablets \(USP41-NF36 2S\)](#)

[Carbinoxamine Maleate \(USP41-NF36 2S\)](#)

[Castor Oil \(USP41-NF36 2S\)](#)

[Cefazolin Sodium \(USP41-NF36 2S\)](#)

[Chlorzoxazone \(USP41-NF36 2S\)](#)

[Chlorzoxazone Tablets \(USP41-NF36 2S\)](#)

[Citalopram Oral Solution \(USP41-NF36 2S\)](#)

[Climbazole \[NEW\] \(USP41-NF36 2S\)](#)

[Clomiphene Citrate Tablets \(USP41-NF36 2S\)](#)

[Cromolyn Sodium \(USP41-NF36 2S\)](#)

[Cyclobenzaprine Hydrochloride \(USP41-NF36 2S\)](#)

[Diphenhydramine Hydrochloride Tablets \[NEW\] \(USP41-NF36 2S\)](#)

[Entecavir \(USP41-NF36 2S\)](#)

[Entecavir Oral Solution \[NEW\] \(USP41-NF36 2S\)](#)

[Epinephrine Inhalation Aerosol \(USP41-NF36 2S\)](#)

[Epinephrine Bitartrate Inhalation Aerosol \(USP41-NF36 2S\)](#)

[Escitalopram Tablets \(USP41-NF36 2S\)](#)

[Gabapentin \(USP41-NF36 2S\)](#)

[Gemcitabine Hydrochloride \(USP41-NF36 2S\)](#)

[Guanidine Hydrochloride \[NEW\] \(USP41-NF36 2S\)](#)

[Hyoscyamine Sulfate \(USP41-NF36 2S\)](#)

[Indomethacin \(USP41-NF36 2S\)](#)

[Isoetharine Mesylate Inhalation Aerosol \(USP41-NF36 2S\)](#)

[Isoproterenol Hydrochloride Inhalation Aerosol \(USP41-NF36 2S\)](#)

[Isoproterenol Hydrochloride and Phenylephrine Bitartrate Inhalation Aerosol \(USP41-NF36 2S\)](#)

[Loperamide Hydrochloride \(USP41-NF36 2S\)](#)

[Lopinavir and Ritonavir Oral Solution \(USP41-NF36 2S\)](#)

[Lopinavir and Ritonavir Tablets \(USP41-NF36 2S\)](#)

[Maprotiline Hydrochloride Tablets \(USP41-NF36 2S\)](#)

[Meloxicam Tablets \(USP41-NF36 2S\)](#)

[Methoxsalen \(USP41-NF36 2S\)](#)

[Methoxsalen Capsules \(USP41-NF36 2S\)](#)

[Methoxsalen Topical Solution \(USP41-NF36 2S\)](#)

[Methscopolamine Bromide \(USP41-NF36 2S\)](#)  
[Methscopolamine Bromide Tablets \(USP41-NF36 2S\)](#)  
[Metoprolol Tartrate Injection \(USP41-NF36 2S\)](#)  
[Oxaliplatin for Injection \(USP41-NF36 2S\)](#)  
[Pimobendan \(USP41-NF36 2S\)](#)  
[Primaquine Phosphate \(USP41-NF36 2S\)](#)  
[Protriptyline Hydrochloride \(USP41-NF36 2S\)](#)  
[Ritonavir Capsules \(USP41-NF36 2S\)](#)  
[Ritonavir Oral Solution \(USP41-NF36 2S\)](#)  
[Ritonavir Tablets \(USP41-NF36 2S\)](#)  
[Sodium Monofluorophosphate \(USP41-NF36 2S\)](#)  
[Stavudine Capsules \(USP41-NF36 2S\)](#)  
[Absorbable Surgical Suture \(USP41-NF36 2S\)](#)  
[Nonabsorbable Surgical Suture \(USP41-NF36 2S\)](#)  
[Testosterone Topical Solution \[NEW\] \(USP41-NF36 2S\)](#)  
[Travoprost Ophthalmic Solution \(USP41-NF36 2S\)](#)  
[Trichlormethiazide Tablets \(USP41-NF36 2S\)](#)  
[Vinblastine Sulfate \(USP41-NF36 2S\)](#)

#### **DIETARY SUPPLEMENT MONOGRAPHS**

[Krill Oil \(USP41-NF36 2S\)](#)  
[Sichuan Lovage Rhizome \[NEW\] \(USP41-NF36 2S\)](#)  
[Sichuan Lovage Rhizome Powder \[NEW\] \(USP41-NF36 2S\)](#)

#### **NF MONOGRAPHS**

[Sodium Lauroyl Sarcosinate \[NEW\] \(USP41-NF36 2S\)](#)

#### **STAGE 4 HARMONIZATION**

[Stage 4 Harmonization](#)

#### **STIMULI TO THE REVISION PROCESS**

[Stimuli to The Revision Process](#)

[A Proposed In Vitro Insulin Cell-Based Bioassay to be Included in USP General Chapter Insulin Assays <121>](#)

[USPC Responses to Comments On Stimuli Article "Modernization of Asbestos Testing in USP Talc"](#)